Can non-invasive biomarkers lead to an earlier diagnosis of Alzheimer's disease?

Abstract

A lack of consensus on the diagnostic criteria used in the clinical setting limits the early diagnosis of Alzheimer’s disease (AD) and increases the backlog of undiagnosed cases. While AD has no cure, the current aim is to diagnose the disease at the pre-symptomatic stage - the key to successful intervention, better understanding, and enabling the admission of improved therapeutic and nonpharmacological interventions. The major issues include the number of people affected, ignorance of the early signs and symptoms by patients, their families and healthcare staff, all of which are exacerbated by the vagueness and variety of symptoms